Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study.

ABSTRACT:

SUBMITTER: Moreau P 

PROVIDER: S-EPMC8361977 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature